Inmune bio, inc.INMB.US Overview
INMB Overall Performance
INMB AI Analysis & Strategy
INMB Recent Performance
0.35%
Inmune bio, inc.
0.81%
Avg of Sector
-1.14%
S&P500
INMB PowerScanner
INMB Key Information
INMB Valuation Metrics
INMB Earnings Table
INMB Profile
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.